-
-
-
-
-
-
-
FDA sets public hearing on psychedelics for September 14, Jefferies sees FDA willing to move on COMP360
-
-
-
-
-
-
-
Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'
-
-
-
-
-
-
-
Wolfe Research Starts Compass Pathways (CMPS) at Outperform
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
-
-
-
-
-
-
BTIG stays Buy on Compass Pathways (CMPS): models may be too conservative following executive order
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
-
-
-
-
-
-
Compass Pathways raises $200 million from warrant exercises
-
443,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

